Cue Biopharma, Inc. (NASDAQ:CUE) Surpasses Earnings and Revenue Estimates

• Cue Biopharma reported an EPS of -$0.09, beating the estimated EPS of -$0.13, marking a positive surprise of 30.77%.
• The company's revenue reached approximately $2.95 million for the quarter, surpassing the estimated $2 million and indicating a 47.70% positive surprise.
• Strategic partnership with Boehringer Ingelheim on CUE-501, with an upfront payment of $12 million and potential milestone payments totaling approximately $345 million.

Cue Biopharma, Inc. (NASDAQ:CUE) is a clinical-stage biopharmaceutical company focused on developing innovative therapies for autoimmune diseases and cancer. The company aims to modulate disease-specific T cells through therapeutic biologics. Operating within the Zacks Medical - Biomedical and Genetics industry, Cue Biopharma is making strides in advancing its drug pipeline and strategic partnerships.

On August 13, 2025, Cue Biopharma reported an earnings per share (EPS) of -$0.09, surpassing the estimated EPS of -$0.13. This result marks a positive surprise of 30.77%, as highlighted by Zacks. The improvement from the previous year's loss of $0.20 per share indicates progress in the company's financial performance. Over the past four quarters, Cue Biopharma has exceeded consensus EPS estimates three times, showcasing its ability to outperform expectations.

In terms of revenue, Cue Biopharma reported approximately $2.95 million for the quarter ending June 2025, exceeding the estimated $2 million. This represents a 47.70% positive surprise, as noted by Zacks. The revenue also increased from $2.66 million a year ago, reflecting the company's growth trajectory. Cue Biopharma has surpassed consensus revenue estimates twice in the last four quarters, demonstrating its potential for consistent revenue generation.

Cue Biopharma's strategic initiatives include a research collaboration and license agreement with Boehringer Ingelheim. This partnership focuses on developing CUE-501, a B cell depletion therapy for autoimmune and inflammatory diseases. The agreement involves an upfront payment of $12 million and potential milestone payments totaling approximately $345 million, providing significant financial support for the company's projects.

Financially, Cue Biopharma has a price-to-earnings (P/E) ratio of -1.45, indicating negative earnings. The price-to-sales ratio is about 7.45, suggesting investor confidence in the company's sales potential. With a debt-to-equity ratio of 1.08, Cue Biopharma maintains a moderate level of debt. The current ratio of 1.03 implies adequate short-term liquidity, supporting the company's operational needs.